Seegene Launches Revolutionary Diagnostic Technologies CURECA™ and STAgora™ at ADLM 2025

Seegene's Groundbreaking Technologies Unveiled at ADLM 2025

Seegene Inc. has officially launched two state-of-the-art technologies, CURECA™ and STAgora™, at the recently concluded ADLM 2025 in Chicago, held from July 29 to 31. This unveiling marks a significant progress towards streamlining laboratory automation and enhancing data-driven disease monitoring in the field of molecular diagnostics.

Dr. Jong-Yoon Chun, the Chairman and CEO of Seegene, presented these innovations amid keen interest from both U.S. and international media, emphasizing the pivotal role these systems will play in redefining the landscape of diagnostics. The premier feature, CURECA™, emerges as the world's first fully unattended PCR automation system, paired with STAgora™, a robust real-time global data analytics platform.

CURECA™: Transforming PCR Automation

CURECA™ is touted as a revolution in PCR testing automation, designed to eliminate manual workflows that have historically plagued molecular testing systems. While many current systems rely heavily on skilled personnel for repetitive tasks, CURECA™ aims to change that by fully automating each step of the PCR testing process.

This includes the pre-treatment stage, which has long been a bottleneck in laboratory efficiency. Seegene emphasizes that full automation hinges on three critical components: operation without the need for specially trained staff, capability for non-stop processing over 24 hours, and the ability to seamlessly handle specimen inputs.

CURECA™ is engineered to meet these criteria. The system’s unique module, CURECA™ Prep, is capable of managing diverse specimen types, including blood, urine, sputum, and stool. This capability aims to overcome automation barriers that have persisted in diagnostics by ensuring that labs can achieve a streamlined, efficient testing process without human intervention.

STAgora™: A New Era in Data Analytics

In parallel, STAgora™ is positioned to transform the way laboratories engage with PCR testing data. Designed as an integrated platform, it facilitates real-time analysis of diagnostic data, allowing laboratories to create contextual insights that inform their workflows.

With over 40 analytical tools at its disposal, STAgora™ doesn't merely serve as a data repository. Instead, it empowers labs to monitor infection trends and co-infection patterns while enabling statistical comparisons across institutions.

As individual test results often lack broader context, STAgora™ allows hospitals to build comprehensive datasets, enabling quicker detection of infection patterns and more informed decision-making in clinical settings. The platform ensures that all shared data is de-identified and formatted to meet the individual requirements of each institution, promoting secure exchange of information at multiple levels—locally, nationally, or globally.

A Vision for a Disease-Free World

During the presentation, Dr. Chun reiterated Seegene’s mission to create a world free from diseases. The introduction of CURECA™ and STAgora™ aligns with the company’s foundational pillars: proprietary PCR technology, an automated assay development system (SGDDS), a technology-sharing initiative, and now cutting-edge automation and data analytics capabilities.

Industry experts attending ADLM 2025 expressed enthusiasm for these advancements. Jamel Giuma, the President and CEO of JTG Consulting Group, remarked on the innovation presented by CURECA™, noting its potential to simplify lab workflows while alleviating pressure on personnel and enhancing operational efficiency.

Dr. Chun underscored the transformative potential of CURECA™ and STAgora™, drawing parallels to the impact of smartphones and electric vehicles in their respective markets. He believes these technologies can redefine diagnostic testing, aiding labs in achieving complete automation and harnessing the full potential of diagnostic data. Ultimately, these efforts align with Seegene's overarching goal of driving advancements towards a disease-free future.

It’s worth noting that both CURECA™ and STAgora™, although showcased at ADLM 2025, remain pre-commercial technologies currently under development, not yet cleared for clinical use in any jurisdiction.